全文获取类型
收费全文 | 471309篇 |
免费 | 24622篇 |
国内免费 | 740篇 |
专业分类
耳鼻咽喉 | 7538篇 |
儿科学 | 16752篇 |
妇产科学 | 14691篇 |
基础医学 | 69826篇 |
口腔科学 | 12434篇 |
临床医学 | 37376篇 |
内科学 | 87658篇 |
皮肤病学 | 11483篇 |
神经病学 | 37241篇 |
特种医学 | 20521篇 |
外国民族医学 | 90篇 |
外科学 | 75065篇 |
综合类 | 8848篇 |
现状与发展 | 1篇 |
一般理论 | 201篇 |
预防医学 | 28489篇 |
眼科学 | 11500篇 |
药学 | 33146篇 |
中国医学 | 1139篇 |
肿瘤学 | 22672篇 |
出版年
2021年 | 3480篇 |
2019年 | 3605篇 |
2018年 | 6558篇 |
2017年 | 5094篇 |
2016年 | 6474篇 |
2015年 | 7237篇 |
2014年 | 8495篇 |
2013年 | 12788篇 |
2012年 | 17662篇 |
2011年 | 17516篇 |
2010年 | 10871篇 |
2009年 | 9374篇 |
2008年 | 16609篇 |
2007年 | 18247篇 |
2006年 | 18135篇 |
2005年 | 18095篇 |
2004年 | 17318篇 |
2003年 | 16721篇 |
2002年 | 16239篇 |
2001年 | 19440篇 |
2000年 | 19820篇 |
1999年 | 16820篇 |
1998年 | 4662篇 |
1997年 | 4121篇 |
1996年 | 3671篇 |
1995年 | 3383篇 |
1992年 | 10792篇 |
1991年 | 10887篇 |
1990年 | 10660篇 |
1989年 | 10353篇 |
1988年 | 9289篇 |
1987年 | 9045篇 |
1986年 | 8531篇 |
1985年 | 8245篇 |
1984年 | 6111篇 |
1983年 | 5183篇 |
1982年 | 3213篇 |
1979年 | 5850篇 |
1978年 | 4281篇 |
1977年 | 3657篇 |
1976年 | 3263篇 |
1975年 | 3977篇 |
1974年 | 4531篇 |
1973年 | 4470篇 |
1972年 | 4211篇 |
1971年 | 4000篇 |
1970年 | 3784篇 |
1969年 | 3460篇 |
1968年 | 3354篇 |
1967年 | 3166篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
3.
Georg Prokop Benedikt Wiestler Daniel Hieber Fynn Withake Karoline Mayer Jens Gempt Claire Delbridge Friederike Schmidt-Graf Nicole Pfarr Bruno Märkl Jürgen Schlegel Friederike Liesche-Starnecker 《International journal of cancer. Journal international du cancer》2023,153(9):1658-1670
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered. 相似文献
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
6.
7.
8.
9.
10.